JP2020530851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530851A5 JP2020530851A5 JP2020508540A JP2020508540A JP2020530851A5 JP 2020530851 A5 JP2020530851 A5 JP 2020530851A5 JP 2020508540 A JP2020508540 A JP 2020508540A JP 2020508540 A JP2020508540 A JP 2020508540A JP 2020530851 A5 JP2020530851 A5 JP 2020530851A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- use according
- patient
- seq
- osimertinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229960003278 osimertinib Drugs 0.000 claims 4
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 102200048955 rs121434569 Human genes 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022109875A JP2022133436A (ja) | 2017-08-21 | 2022-07-07 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548069P | 2017-08-21 | 2017-08-21 | |
| US62/548,069 | 2017-08-21 | ||
| US201862664529P | 2018-04-30 | 2018-04-30 | |
| US62/664,529 | 2018-04-30 | ||
| US201862672153P | 2018-05-16 | 2018-05-16 | |
| US62/672,153 | 2018-05-16 | ||
| PCT/US2018/047031 WO2019040348A1 (en) | 2017-08-21 | 2018-08-20 | COMBINATIONS OF EGFR INHIBITORS AND ANTI-VEGFR -2 HUMAN ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022109875A Division JP2022133436A (ja) | 2017-08-21 | 2022-07-07 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530851A JP2020530851A (ja) | 2020-10-29 |
| JP2020530851A5 true JP2020530851A5 (enExample) | 2020-12-10 |
| JP7135068B2 JP7135068B2 (ja) | 2022-09-12 |
Family
ID=63638326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508540A Active JP7135068B2 (ja) | 2017-08-21 | 2018-08-20 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
| JP2022109875A Withdrawn JP2022133436A (ja) | 2017-08-21 | 2022-07-07 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022109875A Withdrawn JP2022133436A (ja) | 2017-08-21 | 2022-07-07 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11471457B2 (enExample) |
| EP (1) | EP3672633A1 (enExample) |
| JP (2) | JP7135068B2 (enExample) |
| WO (1) | WO2019040348A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022003286A2 (pt) * | 2019-08-23 | 2022-05-24 | Spectrum Pharmaceuticals Inc | Combinação de poziotinibe com inibidores de vegfr2 e métodos de uso da mesma |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2362931T3 (es) | 2002-03-04 | 2011-07-15 | Imclone Llc | Anticuerpos humanos específicos contra kdr y usos de los mismos. |
| ES2791308T3 (es) | 2011-07-27 | 2020-11-03 | Astrazeneca Ab | Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer |
| TW201622744A (zh) | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | 癌症之組合療法 |
-
2018
- 2018-08-20 US US16/633,230 patent/US11471457B2/en active Active
- 2018-08-20 EP EP18772972.8A patent/EP3672633A1/en active Pending
- 2018-08-20 WO PCT/US2018/047031 patent/WO2019040348A1/en not_active Ceased
- 2018-08-20 JP JP2020508540A patent/JP7135068B2/ja active Active
-
2022
- 2022-07-07 JP JP2022109875A patent/JP2022133436A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rolfo et al. | Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors | |
| JP2009505676A5 (enExample) | ||
| JP2019107018A5 (enExample) | ||
| JP2019214586A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2019521087A5 (enExample) | ||
| JP2020500525A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| JP2019506444A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| IL276515B1 (en) | PD–L1-specific antibodies and methods of using them | |
| RU2016148645A (ru) | Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого | |
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| FI3083686T4 (fi) | Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja | |
| JP2016505635A5 (enExample) | ||
| RU2017136709A (ru) | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr | |
| US20220387488A1 (en) | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies | |
| US20220387571A1 (en) | Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70 | |
| EA202091841A1 (ru) | Осимертиниб для применения для лечения немелкоклеточного рака легкого | |
| JP2016520082A5 (enExample) | ||
| US20180311374A1 (en) | Targeted cancer therapy | |
| US20210015891A1 (en) | Interleukin-18 mimics and methods of use | |
| JP2014502955A5 (enExample) | ||
| FI3452513T3 (fi) | Humanisoituja anti-il-1r3-vasta-aineita |